PO.TB07.01 · 肿瘤生物学
诱导多能干细胞(iPSCs)可诱发功能性细胞毒性T细胞应答的证据:为iPSC来源的癌症疫苗铺平道路
Evidence of functional cytotoxic T-cell responses to induced pluripotent stem cells (IPSCs): Paving the way for IPSC-derived cancer vaccines
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:近期研究表明,异体或自体iPSC疫苗均代表了一种颇具前景的癌症免疫治疗新策略,可用于预防性或治愈性目的,尤其针对具有干性特征、转移扩散风险高的侵袭性肿瘤。我们此前已在小鼠模型中证实了这一癌症疫苗策略的体内疗效(Kishi等,Front Med,2021),但在人类细胞背景下iPSCs的免疫原性仍属未知。
方法:为在人类细胞中解决这一问题,我们从HLA-A2+供者采集的外周血单个核细胞(PBMC)批次建立了混合淋巴细胞反应(MLR)生物测定。该测定通过共培养CD8+初始T细胞与来源于CD14+单核细胞的树突状细胞(DCs)进行标准化,后者负载了由多株iPSCs系生成的iPSC来源裂解物。使用增殖实验、表型分析和细胞因子分泌评估经裂解物致敏的CD8+T细胞。经裂解物致敏的CD8+T细胞的细胞毒性功能通过与多株HLA-A2+人癌细胞系共培养后评估,包括黑色素瘤(SK-MEL5)、三阴性乳腺癌(MAD-MB-231)和人结直肠腺癌(SW-620)。
结果:经分化和成熟后,负载iPSC来源裂解物的DCs高表达CD80、CD11c、CD86、MHC I类和II类分子。与这些DCs共培养后,在所有测试条件下,经致敏的CD8+T细胞相较于对照T淋巴细胞对癌细胞系表现出显著增强的裂解能力。这些活化T细胞呈现出以CD137、CD107a、IFN-gamma和TNF-alpha表达为标志的效应表型,提示iPSCs能够传递广泛的免疫原性表位。我们进一步使用单细胞RNA测序分析了经不同iPSCs致敏的CD8+T细胞中alpha/beta TCR库的克隆多样性。共鉴定出16个不同的T细胞簇,包括一个由CD8+ Flt3+T细胞组成的小群体和一个由CD83+ CD8+T细胞组成的优势簇,后者包含超过1,000个独特的alpha/beta TCR克隆。这些T细胞的单细胞RNA测序分析正在进行中。
结论:我们的结果提供了有力证据,表明iPSCs能够有效活化DCs并诱导产生表型活化、功能完备的细胞毒性T细胞。该策略在开发现货型、基于iPSC的癌症疫苗方面具有巨大潜力,可利用iPSC来源细胞广泛的抗原库,针对在最具侵袭性癌症(如非小细胞肺癌、胰腺癌和胶质母细胞瘤)中表达的癌症干细胞基因产生免疫应答。
查看英文原文 English abstract
Background: Recent studies have demonstrated that both allogeneic or autologous iPSC-based vaccines represent a promising new approach to preventive or curative cancer immunotherapy strategies particularly against aggressive tumors harboring stemness features with high risk of metastatic spread. We have previously demonstrated the in vivo efficacy of this cancer vaccine strategy in mice models (Kishi et al, Front Med, 2021) but the immunogenicity of iPSCs in the context of human cells remains unknown.
Methods:To address this issue in human cells, we developed a Mixed Lymphocyte Reaction (MLR) bioassay from collected batches of peripheral blood mononuclear cells (PBMC) from HLA-A2+ donors. The assay was standardized by co-culturing CD8+ naïve T Cells and Dendritic Cells (DCs) derived from CD14+ monocytes which were loaded with iPSCs derived-lysates generated from several iPSCs lines. The primed CD8+ T cells with the lysates were assessed using proliferation assays, phenotypic profiling, and cytokine secretion. Cytotoxic function of the primed CD8+ T cells was assessed after co-culture with several HLA A2+ human cancer cell lines, including melanoma (SK-MEL5), triple negative breast carcinoma (MAD-MB-231) and human colorectal adenocarcinoma (SW-620).
Results: After differentiation and maturation, DCs loaded with iPSC-derived lysates highly expressed CD80, CD11c, CD86, MHC class I and II. After co-culture with these DCs, in all tested conditions, primed CD8+T cells exhibited significantly enhanced lysis of the cancer cell lines as compared to control T lymphocytes. These activated T cells displayed an effector phenotype marked by CD137, CD107a, IFN-gamma, and TNF-alpha expression suggesting that iPSCs were able to transmit a a broad array of immunogenic epitopes. We further analyzed the clonal diversity of the alpha/beta TCR repertoire in CD8+T cells primed with different iPSCs using single-cell RNA sequencing. Sixteen distinct T cell clusters were identified, including a minor population of CD8+ Flt3+T cells and a dominant cluster of CD83+ CD8+T cells comprising over 1,000 unique alpha/beta TCR clones. Single cell RNA sequence analyses of these T cells are in progress.
Conclusions: Our results provide strong evidence that iPSCs can effectively activate DCs and induce the generation of phenotypically activated and functionally competent cytotoxic T cells. This strategy holds great potential for the development of off-the-shelf, IPSC-based cancer vaccines leveraging the broad antigenic repertoire of iPSC-derived cells able to generate immune response against cancer stem cell genes expressed in the most aggressive cancers such as non-small cell lung cancer, pancreas cancer and glioblastoma.
利益披露 Disclosure
V. Feyants, None..
C. Martel, None..
C. Desterke, None..
M. Maatoug, None..
D. Chaker, None..
A. G. Turhan, None..
A. Bennaceur Griscelli, None..
F. Griscelli, None.